- Correspondence to Nouf S Al-Fadel, Vigilance and Benefit-Risk Assessment Executive Directorate, Saudi Food and Drug Authority, PO Box 6288, Riyadh 13312, Saudi Arabia;
- Received January 8, 2016
- Revised February 7, 2016
- Accepted February 25, 2016
- First published March 21, 2016.
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.